Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field
Differentiation of normal pituitary from abnormal tumor tissue remains a surgical challenge despite improvements in optical visualization technology for pituitary adenoma (PA) surgery. During neurosurgical procedures for other tumor types, 5-aminolevulinic acid (5-ALA) has become a focus of investigation based on its high specificity in differentiating tumor tissue. However, the role of 5-ALA and other optical fluorescent agents in PA surgery remains less clear.
To perform a systematic review on the use of various optical fluorescent agents in PA surgery.
Using PRISMA guidelines, a systematic literature review to identify reports describing 5-ALA and other optical agents for fluorescence-guided surgery for PA was performed. Eleven research studies met inclusion criteria and were reviewed.
In two studies, 5-ALA was not shown to be effective in aiding PA resection using standard neurosurgical endoscopic/microscopic approaches. 5-ALA photodynamic therapy was evaluated in two in-vitro models with inconsistent results. Intraoperative use of indocyanine green (ICG) concluded with varying results, but showed a tendency towards improved differentiation of functional PA. OTL38 showed potential for intraoperative identification of nonfunctioning PA, particularly in tumors with high folate receptor expression. One study reported clinically useful fluorescence following sodium fluorescein administration.
We conclude that selected optical fluorescent agents, including ICG and folate receptors, are most likely to hold promise for clinical use in differentiating PA from normal tissue.
KeywordsPituitary adenoma 5-Aminolevulinic acid Fluorescence guided surgery Optical fluorescence agents
Compliance with ethical standards
Conflict of interest
Author Stephanie Wan-Ting Chang declares that she has no conflict of interest. Author Daniel A. Donoho declares that he has no conflict of interest. Author Gabriel Zada declares that he has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 4.Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T, Perkovic Z, Giljevic Z, Jelcic J, Paladino J, Korsic M, Aganovic I (2011) Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience. Endocrinol Invest 32:e382–e385. https://doi.org/10.3275/7858 Google Scholar
- 7.Berkmann S, Schlaffer S, Nimsky C, Fahlbusch R, Buchfelder M (2014) Follow-up and long-term outcome of nonfunctioning pituitary adenoma operated by transsphenoidal surgery with intraoperative high-field magnetic resonance imaging. Acta Neurochir 156:2233–2243. https://doi.org/10.1007/s00701-014-2210-x CrossRefGoogle Scholar
- 8.Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576. https://doi.org/10.1227/01.neu.0000317304.31579.17 CrossRefGoogle Scholar
- 9.Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JAH, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462CrossRefGoogle Scholar
- 10.Jane JA Jr., Laws ER Jr. (2000) Surgical treatment of pituitary adenomas BTI-Endotext. In: De Groot LJCG, Dungan K et al (ed) MDText.com, Inc., South DartmouthGoogle Scholar
- 12.Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243. https://doi.org/10.1038/nrendo.2014.21 CrossRefGoogle Scholar
- 13.Carr SB, Kleinschmidt-DeMasters BK, Kerr JM, Kiseljak-Vassiliades K, Wierman ME, Lillehei KO (2017) Negative surgical exploration in patients with Cushing’s disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg 8:1–8. https://doi.org/10.3171/2017.5.JNS162901 Google Scholar
- 15.Bellut D, Hlavica M, Muroi C, Woernle CM, Schmid C, Bernays RL (2012) Impact of intraoperative MRI-guided transsphenoidal surgery on endocrine function and hormone substitution therapy in patients with pituitary adenoma. Swiss Med Wkly 142:w13699. https://doi.org/10.4414/smw.2012.13699 Google Scholar
- 25.Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1–G24. https://doi.org/10.1530/EJE-17-0796 CrossRefGoogle Scholar
- 30.Verstegen MJT, Tummers QRJG, Schutte PJ, Pereira AM, van Furth WR, van de Velde CJH, Malessy MJA, Vahrmeijer AL (2016) Intraoperative identification of a normal pituitary gland and an adenoma using near-infrared fluorescence imaging and low-dose indocyanine green. Oper Neurosurg 12:260–268. https://doi.org/10.1227/NEU.0000000000001328 CrossRefGoogle Scholar
- 31.Cho SS, Zeh R, Pierce JT, Jeon J, Nasrallah M, Adappa ND, Palmer JN, Newman JG, White C, Kharlip J, Snyder P, Low P, Singhal S, Grady MS, Lee JYK (2018) Folate receptor near-infrared optical imaging provides sensitive and specific intraoperative visualization of nonfunctional pituitary adenomas. Oper Neurosurg. https://doi.org/10.1093/ons/opy034 Google Scholar
- 32.Lee JYK, Cho SS, Zeh R, Pierce JT, Martinez-Lage M, Adappa ND, Palmer JN, Newman JG, Learned KO, White C, Kharlip J, Snyder P, Low PS, Singhal S, Grady MS (2018) Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. J Neurosurg 129:390–403. https://doi.org/10.3171/2017.2.JNS163191 CrossRefGoogle Scholar
- 36.Marbacher S, Klinger E, Schwyzer L, Fischer I, Nevzati E, Diepers M, Roelcke U, Fathi AR, Coluccia D, Fandino J (2014) Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases. Neurosurg Focus 36:E10. https://doi.org/10.3171/2013.12.FOCUS13464 CrossRefGoogle Scholar
- 42.Nemes A, Fortmann T, Poeschke S, Greve B, Prevedello D, Santacroce A, Stummer W, Senner V, Ewelt C (2016) 5-ALA fluorescence in native pituitary adenoma cell lines: resection control and basis for photodynamic therapy (PDT)? PLoS ONE 11:e0161364. https://doi.org/10.1371/journal.pone.0161364 CrossRefGoogle Scholar
- 43.Neumann LM, Beseoglu K, Slotty PJ, Senger B, Kamp MA, Hänggi D, Steiger HJ, Cornelius JF (2016) Efficacy of 5-aminolevulinic acid based photodynamic therapy in pituitary adenomas-experimental study on rat and human cell cultures. Photodiagn Photodyn Ther 14:77–83. https://doi.org/10.1016/j.pdpdt.2016.02.006 CrossRefGoogle Scholar